A new modifiction of trabeculectomy

A new technique which was found to improve surgical results for trabeculectomy

Medically uncontrolled primary open-angle glaucoma (POAG) cases were included in the study as group 1. Baseline examinations included: BCVA, IOP measurement with an applanation tonometer, biomicroscopy, gonioscopy and funduscopy. Visual fields, OCT and HRT examinations were also obtained as needed.

As a surgical technique, we formed a fornix-based conjunctival flap in the superior quadrant. After the dissection of a superficial limbus-based square shaped 4mm × 4mm scleral flap, a second deep scleral flap about 3mm × 3mm was carefully dissected. Schlemm's canal was deroofed and the deep scleral flap excised after Descement's membrane was reached. At that stage, an inferotemporal clear corneal side-port was created with a 20 G MVR knife, an anterior chamber maintainer (ACM) was positioned and kept closed. Following the excision of trabeculum tissue, peripheral iridectomy was performed. Superficial scleral flap was sutured with a 10/0 monofilament suture at the corners. Drainage of balanced salt solution through the ACM was allowed and flow of BSS under the flap was observed. Depending on the amount of filtration, sutures were adjusted in number (between 2 to 6) and tension. Tenon and conjunctiva were sutured with 8.0 vicryl and a well formed bleb was observed at the end of the surgeries.

Related Videos
Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase
2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent
Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in
Investigating the effects of canaloplasty on corneal epithelium
POAG study hope to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma
Gonio-intervention robot-assisted glaucoma surgical procedure offers high precision
Investigating best practices for MicroPulse transscleral therapy for glaucoma
Bimatoprost implant successfully lowers IOP in Phase 3 of the ARTEMIS study
© 2023 MJH Life Sciences

All rights reserved.